📇 Rhumatologue · LE MANS · (72) · Libéral
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Praticien-chercheur
18 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
77.4 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CABINET DU DR NOHA SAAD
SATIM 58 AVENUE DU GENERAL DE GAULLE, 72000 LE MANS
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Arthritis & rheumatology (Hoboken, N.J.) · 2022
ObjectiveTo provide updated guidelines for pharmacologic management of juvenile idiopathic arthritis (JIA), focusing on treatment of oligoarthritis, temporomandibular joint (TMJ) arthritis, and systemic JIA with and without macrophage activation syndrome. Recommendations regarding tapering and discontinuing treatment in inactive systemic JIA are also provided.MethodsWe developed clinically relevant Patient/Population, Intervention, Comparison, and Outcomes questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation approach was used to rate the quality of evidence (high, moderate, low, or very low). A Voting Panel including clinicians and patients/caregivers achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations.ResultsSimilar to those published in 2019, these JIA recommendations are based on clinical phenotypes of JIA, rather than a specific classification schema. This guideline provides recommendations for initial and subsequent treatment of JIA with oligoarthritis, TMJ arthritis, and systemic JIA as well as for tapering and discontinuing treatment in subjects with inactive systemic JIA. Other aspects of disease management, including factors that influence treatment choice and medication tapering, are discussed. Evidence for all recommendations was graded as low or very low in quality. For that reason, more than half of the recommendations are conditional.ConclusionThis clinical practice guideline complements the 2019 American College of Rheumatology JIA and uveitis guidelines, which addressed polyarthritis, sacroiliitis, enthesitis, and uveitis. It serves as a tool to support clinicians, patients, and caregivers in decision‐making. The recommendations take into consideration the severity of both articular and nonarticular manifestations as well as patient quality of life. Although evidence is generally low quality and many recommendations are conditional, the inclusion of caregivers and patients in the decision‐making process strengthens the relevance and applicability of the guideline. It is important to remember that these are recommendations. Clinical decisions, as always, should be made by the treating clinician and patient/caregiver.
Arthritis care & research · 2022
ObjectiveTo provide updated guidelines for pharmacologic management of juvenile idiopathic arthritis (JIA), focusing on treatment of oligoarthritis, temporomandibular joint (TMJ) arthritis, and systemic JIA with and without macrophage activation syndrome. Recommendations regarding tapering and discontinuing treatment in inactive systemic JIA are also provided.MethodsWe developed clinically relevant Patient/Population, Intervention, Comparison, and Outcomes questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation approach was used to rate the quality of evidence (high, moderate, low, or very low). A Voting Panel including clinicians and patients/caregivers achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations.ResultsSimilar to those published in 2019, these JIA recommendations are based on clinical phenotypes of JIA, rather than a specific classification schema. This guideline provides recommendations for initial and subsequent treatment of JIA with oligoarthritis, TMJ arthritis, and systemic JIA as well as for tapering and discontinuing treatment in subjects with inactive systemic JIA. Other aspects of disease management, including factors that influence treatment choice and medication tapering, are discussed. Evidence for all recommendations was graded as low or very low in quality. For that reason, more than half of the recommendations are conditional.ConclusionThis clinical practice guideline complements the 2019 American College of Rheumatology JIA and uveitis guidelines, which addressed polyarthritis, sacroiliitis, enthesitis, and uveitis. It serves as a tool to support clinicians, patients, and caregivers in decision‐making. The recommendations take into consideration the severity of both articular and nonarticular manifestations as well as patient quality of life. Although evidence is generally low quality and many recommendations are conditional, the inclusion of caregivers and patients in the decision‐making process strengthens the relevance and applicability of the guideline. It is important to remember that these are recommendations. Clinical decisions, as always, should be made by the treating clinician and patient/caregiver.
The Journal of rheumatology · 2018
Objective. We tested the discriminatory capacity of diffusion-weighted magnetic resonance imaging (DWI) and its potential as an objective measure of treatment response to tumor necrosis factor inhibition in ankylosing spondylitis (AS). Methods. Three cohorts were studied prospectively: (1) 18 AS patients with Bath Ankylosing Spondylitis Disease Activity Index > 4, and erythrocyte sedimentation rate > 25 and/or C-reactive protein > 10 meeting the modified New York criteria for AS; (2) 20 cases of nonradiographic axial spondyloarthritis (nr-axSpA) as defined by the Assessment of Spondyloarthritis international Society (ASAS) criteria; and (3) 20 non-AS patients with chronic low back pain, aged between 18 and 45 years, who did not meet the imaging arm of the ASAS criteria for axSpA. Group 1 patients were studied prior to and following adalimumab treatment. Patients were assessed by DWI and conventional magnetic resonance imaging (MRI), and standard nonimaging measures. Results. At baseline, in contrast to standard nonimaging measures, DWI apparent diffusion coefficient (ADC) values showed good discriminatory performance [area under the curve (AUC) > 80% for Group 1 or 2 compared with Group 3]. DWI ADC values were significantly lower posttreatment (0.45 ± 0.433 before, 0.154 ± 0.23 after, p = 0.0017), but had modest discriminating capacity comparing pre– and posttreatment measures (AUC = 68%). This performance was similar to the manual Spondyloarthritis Research Consortium of Canada (SPARCC) scoring system. Conclusion. DWI is informative for diagnosis of AS and nr-axSpA, and has moderate utility in assessment of disease activity or treatment response, with performance similar to that of the SPARCC MRI score.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Rheumatic diseases clinics of North America · 2023 · Journal Article
Grim A, Veiga KR, Saad N
Frontiers in psychiatry · 2021 · Journal Article
Scheibein F, Stowe MJ, Arya S, Morgan N, et al.
Frontiers in psychiatry · 2021 · Journal Article
Dannatt L, Ransing R, Calvey T, Scheibein F, et al.
Journal of addiction medicine · 2020 · Journal Article
Stowe MJ, Calvey T, Scheibein F, Arya S, et al.
Journal of addiction medicine · 2020 · Journal Article
Calvey T, Scheibein F, Saad NA, Shirasaka T, et al.
Arthritis & rheumatology (Hoboken, N.J.) · 2022 · Journal Article
Onel KB, Horton DB, Lovell DJ, Shenoi S, et al.
Arthritis care & research · 2022 · Journal Article
Onel KB, Horton DB, Lovell DJ, Shenoi S, et al.
Rheumatology and therapy · 2022 · Journal Article
Truong SL, McEwan T, Bird P, Lim I, et al.
Journal of medical imaging and radiation oncology · 2017 · Consensus Statement
Truong SL, Saad NF, Robinson PC, Cowderoy G, et al.
Cureus · 2024 · Case Reports
Aher P, Saad N, Aher A, Priya S, et al.
Journal of clinical medicine · 2023 · Journal Article
Rizk Y, Saad N, Arnaout W, Chalah MA, et al.
Journal of clinical immunology · 2022 · Case Reports
Michniacki TF, Walkovich K, DeMeyer L, Saad N, et al.
International journal of rheumatic diseases · 2014 · Journal Article
Robinson PC, Bird P, Lim I, Saad N, et al.
Cureus · 2024 · Case Reports
Aher P, Saad N, Aher A, Priya S, et al.
Mediterranean journal of rheumatology · 2019 · Journal Article
Mohasseb DMF, Saba EKA, Saad NLM, Sarofeem ADH
The Journal of rheumatology · 2018 · Journal Article
Bradbury LA, Hollis KA, Gautier B, Shankaranarayana S, et al.
Lupus · 2022 · Journal Article
Semo-Oz R, Wagner-Weiner L, Edens C, Zic C, et al.
Plagiarism detection across languages: a comprehensive study of Arabic and English-to-Arabic long documents.
Plagiarism detection across languages: a comprehensive study of Arabic and English-to-Arabic long documents.
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Arthritis care & research · 2022 · Journal Article
Onel KB, Horton DB, Lovell DJ, Shenoi S, et al.
Arthritis & rheumatology (Hoboken, N.J.) · 2022 · Journal Article
Onel KB, Horton DB, Lovell DJ, Shenoi S, et al.